• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva Pharmaceuticals launches generic Erythromycin tablets in U.S.

May 4, 2021 By Sean Whooley

TevaTeva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S.

Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 mg-strength generic Erythromycin tablets, which are a therapeutic equivalent for the reference listed drug Erythromycin from Arbor Pharmaceuticals, according to a news release.

Teva’s generic Erythromycin tablets are indicated for treating a number of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.

Erythromycin treats infections caused by specific, susceptible strains of microorganisms in diseases including respiratory tract infections, listeriosis, skin and skin structure infections, pertussis (whooping cough), diphtheria, erythrasma, intestinal amebiasis, acute pelvic inflammatory disease, conjunctivitis in newborns, pneumonia of infancy, urogenital infections during pregnancy, uncomplicated urethral, endocervical, or rectal infections in adults in specific situations; nongonococcal urethritis in specific situations, primary syphilis and Legionnaires’ Disease.

Teva said IQVIA data from January 2021 claims that U.S. sales of Erythromycin oral tablets total more than $49 million annually.

Filed Under: Business/Financial News, Featured, Pharmaceuticals Tagged With: Teva, Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS